Literature DB >> 23322814

Gout treatment: should we aim for rapid crystal dissolution?

Eliseo Pascual1, Mariano Andrés, Paloma Vela.   

Abstract

Monosodium urate crystal deposition in gout precedes the first attack and, while hyperuricaemia persists, it grows and expands to other sites. Fortunately, it is reversible and slowly dissolves when serum uric acid (SUA) is lowered below its saturation point of about 6.8 mg/dl and with certainty below 6 mg/dl. Crystals finally disappear from joints, taking longer in those patients with longer disease duration, probably because of a larger accumulated load of crystals. The SUA level achieved affects the velocity of crystal dissolution and tophi reduction. Accordingly, by deciding the SUA level cut-off point to be achieved by treatment we are determining the time of crystal disappearance and cure of gout. 6 mg/dl is the usual target level, but lower levels appear appropriate to us, particularly in certain situations.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23322814     DOI: 10.1136/annrheumdis-2012-202594

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  10 in total

1.  Improvement in OMERACT domains and renal function with regular treatment for gout: a 12-month follow-up cohort study.

Authors:  Janitzia Vazquez-Mellado; Ingris Peláez-Ballestas; Rubén Burgos-Vargas; Everardo Alvarez-Hernández; Sergio García-Méndez; Virginia Pascual-Ramos; Marina Rull-Gabayet
Journal:  Clin Rheumatol       Date:  2018-03-15       Impact factor: 2.980

Review 2.  Gout: optimizing treatment to achieve a disease cure.

Authors:  José Antonio Bernal; Neus Quilis; Mariano Andrés; Francisca Sivera; Eliseo Pascual
Journal:  Ther Adv Chronic Dis       Date:  2016-01-12       Impact factor: 5.091

3.  Is urate crystal precipitation a predictor of cardiovascular risk in hyperuricemic patients? A Danish cohort study.

Authors:  Kasper Søltoft Larsen; Anton Pottegård; Hanne Lindegaard; Jesper Hallas
Journal:  Arthritis Res Ther       Date:  2015-10-29       Impact factor: 5.156

4.  Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with febuxostat in adults with gout: a phase IIa, open-label study.

Authors:  Roy Fleischmann; Peter Winkle; Jesse Hall; Shakti Valdez; Sha Liu; Xiaohong Yan; Liz Hicks; Caroline Lee; Jeffrey N Miner; Michael Gillen; Martha Hernandez-Illas
Journal:  RMD Open       Date:  2018-04-09

5.  Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with allopurinol in adults with gout: a phase IIa, open-label study.

Authors:  Roy Fleischmann; Peter Winkle; Jeffrey N Miner; Xiaohong Yan; Liz Hicks; Shakti Valdez; Jesse Hall; Sha Liu; Zancong Shen; Michael Gillen; Martha Hernandez-Illas
Journal:  RMD Open       Date:  2018-02-08

6.  Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Multiple Dose Administration of Verinurad (RDEA3170) and Allopurinol in Adult Male Subjects With Gout.

Authors:  Martin Kankam; Jesse Hall; Michael Gillen; Xiaojuan Yang; Zancong Shen; Caroline Lee; Sha Liu; Jeffrey N Miner; Susan Walker; Vicki Clauson; David Wilson; Mai Nguyen
Journal:  J Clin Pharmacol       Date:  2018-05-07       Impact factor: 3.126

7.  Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Verinurad, a Selective Uric Acid Reabsorption Inhibitor.

Authors:  William B Smith; Jesse Hall; Jolene K Berg; Michal Kazimir; Amy Yamamoto; Susan Walker; Caroline A Lee; Zancong Shen; David M Wilson; Dongmei Zhou; Michael Gillen; Thomas C Marbury
Journal:  Clin Drug Investig       Date:  2018-08       Impact factor: 2.859

8.  Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Administration of Verinurad and Febuxostat in Healthy Male Volunteers.

Authors:  Jesse Hall; Michael Gillen; Xiaojuan Yang; Zancong Shen
Journal:  Clin Pharmacol Drug Dev       Date:  2018-04-24

Review 9.  Physiology of Hyperuricemia and Urate-Lowering Treatments.

Authors:  Caroline L Benn; Pinky Dua; Rachel Gurrell; Peter Loudon; Andrew Pike; R Ian Storer; Ciara Vangjeli
Journal:  Front Med (Lausanne)       Date:  2018-05-31

10.  Verinurad combined with febuxostat in Japanese adults with gout or asymptomatic hyperuricaemia: a phase 2a, open-label study.

Authors:  Masanari Shiramoto; Sha Liu; Zancong Shen; Xiaohong Yan; Amy Yamamoto; Michael Gillen; Yasushi Ito; Jesse Hall
Journal:  Rheumatology (Oxford)       Date:  2018-09-01       Impact factor: 7.580

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.